Pfizer Inc. — 2017 Form 10-K
Reporting period: Fiscal year ended December 31, 2017. This is an annual report, not a standalone fourth-quarter report. Pfizer is a global biopharmaceutical company operating through Innovative Health (IH) and Essential Health (EH).
Financial and operating highlights
| Metric | 2017 |
|---|---|
| Total revenue | Approximately $52.5 billion |
| IH revenue | Approximately $31.4 billion |
| EH revenue | Approximately $21.1 billion |
| Revenue outside the U.S. | $26.5 billion, or 50% of total revenue |
| R&D expense | Approximately $7.7 billion |
| Products with over $1 billion in direct product and/or alliance revenue | Nine; together they represented 46% of total revenue |
The supplied filing text does not provide clear values for net income, operating profit, cash flow, margins, total debt, cash balances, or liquidity ratios; those statements are incorporated by reference to the 2017 Financial Report. It also does not provide a clear year-over-year revenue comparison.
Material changes and notable developments
- Pfizer completed the sale of its Hospira Infusion Systems net assets to ICU Medical on February 3, 2017, for consideration of up to approximately $900 million, including contingent consideration and other forms of payment.
- U.S. generic Viagra launched in December 2017 following a patent-litigation settlement. Pfizer expected U.S. and Canadian Viagra revenue to move from IH to EH beginning in 2018.
- Pfizer announced a review of strategic alternatives for Consumer Healthcare, including a possible spin-off, sale, or other transaction; a decision was expected during 2018.
- In January 2018, Pfizer announced it would end internal neuroscience discovery and early-development work and reallocate resources; tanezumab and rare neuromuscular-disorder programs were not affected.
- The company reported nine products above $1 billion in 2017 versus seven IH products and one EH product identified in its segment-level disclosures. Segment classifications and product revenue reporting may affect direct comparisons.
Outlook, risks, and unusual items
- The excerpt references 2018 financial guidance but does not provide the guidance figures. Pfizer cited potential effects from foreign exchange, product competition, costs, and other assumptions.
- Management described pricing and reimbursement pressure from governments, insurers, and pharmacy benefit managers as an ongoing challenge. Generic and biosimilar competition and loss of exclusivity could materially reduce sales; Pfizer identified Lyrica’s U.S. patent expiration in 2018 as a relevant exposure.
- Nine products accounted for 46% of revenue, creating concentration risk. The filing also highlights patent challenges and competitive risks to major products, including Prevnar 13, Xeljanz, and Xtandi.
- Manufacturing and regulatory matters include an FDA warning letter concerning Hospira’s McPherson, Kansas facility and a warning letter concerning Meridian sites in St. Louis. The McPherson facility’s status was upgraded to Voluntary Action Indicated in January 2018; corrective actions at the St. Louis sites remained ongoing.
- Pfizer reported periodic shortages of select raw materials in 2017, but anticipated no significant operational impact in 2018. Puerto Rico operations were affected by 2017 hurricanes.
- The Tax Cuts and Jobs Act was enacted in December 2017. The supplied text refers to tax-related financial effects but does not state a clear amount.
- Other principal risks include litigation and contingencies, product safety and regulatory approval, foreign exchange, international price controls, wholesaler concentration, cybersecurity, and integration or execution risks from acquisitions and strategic initiatives.
Key facts for investors to verify
- Review the incorporated 2017 Financial Report for audited income, cash-flow, balance-sheet, debt, liquidity, margin, and year-over-year figures.
- Check the company’s 2018 financial guidance and assumptions, which are referenced but not stated in the supplied text.
- Assess exposure to loss of exclusivity and generic or biosimilar launches, especially for Lyrica and Viagra, and evaluate the replacement growth expected from newer products.
- Monitor FDA remediation progress at the McPherson and St. Louis facilities and any resulting supply or approval constraints.
- Follow the Consumer Healthcare strategic review and any associated costs, transaction terms, or changes to Pfizer’s portfolio.
- Review the detailed tax disclosures and legal-contingency notes for amounts and potential effects not provided in this excerpt.